[ad_1]
ORLANDO, FLORIDA, UNITED STATES – 2021/04/10: Johnson & Johnson COVID-19 vial and box seen at a vaccination site. Doses of the Johnson & Johnson vaccine are being given throughout the state of Florida despite a small number of patients who have experienced side effects, including blood clots. (Photo by Paul Hennessy / SOPA Images / LightRocket via Getty Images)
SOPA Pictures | LightRocket | Getty Images
Johnson & Johnson and AstraZeneca are conducting early-stage research on whether potential changes to their Covid-19 vaccines could reduce or eliminate the risk of rare, but serious, blood clots associated with injections.
The problem with blood clotting, which some scientists refer to as vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been linked to both injections. Scientists have uncovered clues to the formation of the clots, raising hopes of a possible reengineering of the shots, a person familiar with the matter told CNBC.
The Wall Street Journal reported the news earlier on Tuesday.
In a statement to CNBC, J&J said he supports “further research and analysis as we work with medical experts and global health authorities.”
“Johnson & Johnson remains committed to helping end this deadly pandemic as quickly as possible, and we continue to believe in the positive benefit-risk profile of our vaccine,” the company said.
AstraZeneca said it “is actively working with regulators and the scientific community to understand these extremely rare blood clotting events, including information allowing early diagnosis and intervention, and appropriate treatment.”
The Food and Drug Administration said in April it was adding a warning label to J & J’s Covid vaccine, citing the blood clotting disorder as a rare side effect.
On Monday, the FDA said it was adding another warning to J&J’s label, saying the hit was linked to a serious, but rare, autoimmune disease known as Guillain-Barre syndrome.
About 100 preliminary reports of Guillain-Barre were detected after the administration of 12.8 million doses of the J&J vaccine, according to the CDC. Cases reported after receiving the J&J vaccine largely occurred around two weeks after vaccination and mostly in men, many of whom are 50 years of age and older, according to the CDC. Available data does not show a similar pattern with Pfizer’s or Moderna’s vaccine, the agency said.
On April 13, the FDA and CDC called on states to temporarily halt use of J & J’s vaccine “out of caution” while they investigated six women, ages 18 to 48, who developed Cerebral venous sinus thrombosis, or CVST, in combination with low blood platelet count. within approximately two weeks of receiving the injection.
They recommended resuming use of the vaccine 10 days later after the CDC determined that the benefits of the inoculations outweighed their risks.
Tuesday’s Journal report noted that the vaccine modification may require changes in property rights or regulatory approvals.
[ad_2]
Source link